Amarin Corporation PLCNASDAQ:AMRN

Help
Symbol Lookup
    No Matches were found for
    Additional matches for ...
     
    Go
    OverviewChartsNewsFundamentalsEarningsReportsCalendarOptionsTechnical Insight

    Symbol Lookup

    Close

    Search Criteria

    Name or Symbol

    Security Type

    Fund Categories

    Market

    Expiration Filter

    Chain Type

    Submit
    Thursday May 23, 2013 6:59 AM ET. Data delayed 15 minutes.
    6.89
    0.00 (0.00%)
    Price HistoryRefresh
    Bid/Lots
    6.80/15
    Ask/Lots
    7.28/2
    Open/Prev Close
    0.00/6.89
    Day Range
    -----
    52-Week Range
    6.34-15.96
    Vol/Avg Daily Vol
    0.0/3.8M

    TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

    Open a New Account, or Login if you're a client.

    AMRN Headlines

    Go
    view headlines only »

    Yesterday

    Amarin Surges 5% - Publishes Patent Application Notification
    21 hours ago by Midnight Trader
    Companies Mentioned: AMRN
    09:31 AM EDT, 05/22/2013 (MidnightTrader) -- Amarin Corportation plc (AMRN) was up 5% this morning on an publication of the Notification of Patent for U.S. Application tied to Amarin's combination product of Vascepa and Statin Therapy. This particu...
    09:31 AM EDT, 05/22/2013 (MidnightTrader) -- Amarin Corportation plc (AMRN) was up 5% this morning on an publication of the Notification of Patent for U.S. Application tied to Amarin's combination product of Vascepa and Statin Therapy. This part...
    MTNewswires' Pre-Market Trading Ranges
    22 hours ago by Midnight Trader
    Companies Mentioned: IBIO, LOW, NTAP, ONCY, PFE, ST, SKS, SPLS, TOL, ZLC, AMRN, CCL
    08:27 AM EDT, 05/22/2013 (MidnightTrader) -- Some of the stocks moving on news-driven events in today's pre-market, including their respective trading ranges: UPSIDE MOVERS SKS: 13.67 TO 16.37 ONCY: 2.72 TO 2.92 IBIO: 0.379 TO 0.550 NTAP: 36.63 TO ...
    08:27 AM EDT, 05/22/2013 (MidnightTrader) -- Some of the stocks moving on news-driven events in today's pre-market, including their respective trading ranges: UPSIDE MOVERS SKS: 13.67 TO 16.37 ONCY: 2.72 TO 2.92 IBIO: 0.379 TO 0.550 NTAP: 36.63 ...
    MTNewswires' Pre-Market News Movers
    22 hours ago by Midnight Trader
    Companies Mentioned: IBIO, LOW, NTAP, ONCY, PFE, ST, SKS, SPLS, TOL, ZLC, AMRN, CCL
    08:25 AM EDT, 05/22/2013 (MidnightTrader) -- Some of the stocks moving on news-driven events in today's pre-market include: SKS, +19.24% ONCY, +12.13% IBIO, +42.52% NTAP, +6.52% AMRN, +4.58% ZLC, +17.04% PFE, +2.57% TOL, +3.03% SPLS, -3.39% LOW, -2....
    08:25 AM EDT, 05/22/2013 (MidnightTrader) -- Some of the stocks moving on news-driven events in today's pre-market include: SKS, +19.24% ONCY, +12.13% IBIO, +42.52% NTAP, +6.52% AMRN, +4.58% ZLC, +17.04% PFE, +2.57% TOL, +3.03% SPLS, -3.39% LOW, ...
    Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
    6:00AM ET on Wednesday May 22, 2013 by GlobeNewswire
    Companies Mentioned: AMRN

    Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy.

    Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has ...

    May 9, 2013

    Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
    4:05PM ET on Thursday May 09, 2013 by GlobeNewswire
    Companies Mentioned: AMRN

    Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2013 and provided an update on company operations.

    Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 20...

    ← Newer123Older →

    Peers Headlines

    Yesterday

    TESARO to Present at the Deutsche Bank 38th Annual 2013 Health Care Conference
    14 hours ago by GlobeNewswire
    Companies Mentioned: TSRO

    TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President, will present at the Deutsche Bank 38 Annual 2013 Health Care Conference at the Westin Boston Waterfront Hotel on W...

    Celldex Therapeutics to Present at Two Upcoming Investor Conferences
    20 hours ago by GlobeNewswire
    Companies Mentioned: CLDX, DB

    Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 38 Annual Healthcare Conference in Boston on May 29, 2013 at 4:10 p.m. ...

    May 17, 2013

    Puma Biotechnology Says No Comment on Trading as Stock Hits Year Top on Heavy Volume
    3:09PM ET on Friday May 17, 2013 by Midnight Trader
    Companies Mentioned: PBYI
    03:09 PM EDT, 05/17/2013 (MidnightTrader) -- Puma Biotechnology (PBYI), a development stage biopharmaceutical company, says its policy is not to comment on trading activity after its shares touched a 52-week high on almost double the daily averag...
    Puma Biotechnology Comment on Trading Activity
    2:34PM ET on Friday May 17, 2013 by Business Wire
    Companies Mentioned: PBYI

    Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding today's trading in the Company's common stock. It is the Company's policy not...

    May 16, 2013

    Tesaro Spikes 14%, Hits 52-Week Top on Positive Results for Breast/Ovarian Cancer Treatment
    2:55PM ET on Thursday May 16, 2013 by Midnight Trader
    Companies Mentioned: TSRO
    02:55 PM EDT, 05/16/2013 (MidnightTrader) -- Tesaro (TSRO) shares have jumped 14% to $36.05, and set a new 52-week high of $36.80, after the company said it will present data at the upcoming American Society of Clinical Oncology conference that c...
    TESARO Announces Presentation of Niraparib Clinical Data at the 2013 ASCO Annual Meeting
    8:00AM ET on Thursday May 16, 2013 by GlobeNewswire
    Companies Mentioned: TSRO

    -- Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer

    -- Phase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-Year

    -- Phase 3 Trial in Patients With Breast Cancer on Track to Initiate in...

    May 14, 2013

    Puma Biotechnology to Present at UBS Global Healthcare Conference
    4:15PM ET on Tuesday May 14, 2013 by Business Wire
    Companies Mentioned: PBYI

    Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Compan...

    May 13, 2013

    Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
    6:00AM ET on Monday May 13, 2013 by PR Newswire
    Companies Mentioned: LXRX

    Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 PM PDT (6:...

    May 10, 2013

    Lexicon Pharma Advances LX4211 in Type 1 Diabetes Phase 2 Trial
    7:05AM ET on Friday May 10, 2013 by Midnight Trader
    Companies Mentioned: LXRX
    07:05 AM EDT, 05/10/2013 (MidnightTrader) -- Lexicon Pharmaceuticals, Inc. (LXRX) is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having completed the open-label, pionee...
    Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
    6:01AM ET on Friday May 10, 2013 by PR Newswire
    Companies Mentioned: LXRX

    Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pion...

    ← Newer123Older →

    K=Thousands, M=Millions, B=Billions, TTM=Trailing 12 Month, MRQ=Most Recent Quarter, FYR=Fiscal Year End, NM=Not Meaningful, NA=Not Available

    GAAP = Generally Accepted Accounting Principles used in Financial Statements issued by the company, Non-GAAP = Adjusted Operating Earnings or Revenue used in comparison to Analyst Estimates. Adjustments are typically one-time gains or losses

    6:59 AM May 23, 2013
    Copyright ©2013 TD Waterhouse Canada Inc. All rights reserved.
    Privacy Policy | Internet Security | Legal
    Quotes, News, and Fundamentals provided by
    View restrictions
    News provided by